Gyre Therapeutics (NASDAQ:GYRE) Shares Up 1.4% - Time to Buy?

Key Points

• Gyre Therapeutics' stock increased by 1.4% on Wednesday, trading at $7.02 with a market cap of $658.20 million and a P/E ratio of 351.18.
• The company reported quarterly earnings of $0.03 EPS on revenue of $22.06 million, which fell short of the consensus estimate of $28.40 million.
• Significant hedge fund activity includes Wells Fargo and Bank of America increasing their stakes, contributing to 23.99% of the stock being owned by institutional investors.

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) rose 1.4% on Wednesday . The stock traded as high as $7.06 and last traded at $7.02. Approximately 77,301 shares were traded during trading, a decline of 0% from the average daily volume of 77,415 shares. The stock had previously closed at $6.92.

Gyre Therapeutics Stock Performance

The company's fifty day moving average price is $7.69 and its 200 day moving average price is $9.23. The firm has a market capitalization of $657.26 million, a price-to-earnings ratio of 349.17 and a beta of 1.80.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. Gyre Therapeutics had a net margin of 7.20% and a return on equity of 9.73%. The business had revenue of $22.06 million during the quarter, compared to analyst estimates of $28.40 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GYRE. Wells Fargo & Company MN boosted its holdings in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares during the period. Barclays PLC boosted its holdings in shares of Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after buying an additional 1,255 shares during the period. Northern Trust Corp boosted its holdings in shares of Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after buying an additional 8,624 shares during the period. Bank of America Corp DE boosted its holdings in shares of Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock valued at $84,000 after buying an additional 1,996 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Gyre Therapeutics by 15,083.3% during the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after purchasing an additional 1,810 shares during the period. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.